TRIM37 controls cancer-specific vulnerability to PLK4 inhibition

Franz Meitinger (), Midori Ohta, Kian-Yong Lee, Sadanori Watanabe, Robert L. Davis, John V. Anzola, Ruth Kabeche, David A. Jenkins, Andrew K. Shiau, Arshad Desai () and Karen Oegema ()
Additional contact information
Franz Meitinger: Ludwig Institute for Cancer Research
Midori Ohta: Ludwig Institute for Cancer Research
Kian-Yong Lee: Ludwig Institute for Cancer Research
Sadanori Watanabe: Ludwig Institute for Cancer Research
Robert L. Davis: Ludwig Institute for Cancer Research
John V. Anzola: Ludwig Institute for Cancer Research
Ruth Kabeche: Ludwig Institute for Cancer Research
David A. Jenkins: Ludwig Institute for Cancer Research
Andrew K. Shiau: Ludwig Institute for Cancer Research
Arshad Desai: Ludwig Institute for Cancer Research
Karen Oegema: Ludwig Institute for Cancer Research

Nature, 2020, vol. 585, issue 7825, 440-446

Abstract: Abstract Centrosomes catalyse the formation of microtubules needed to assemble the mitotic spindle apparatus1. Centrosomes themselves duplicate once per cell cycle, in a process that is controlled by the serine/threonine protein kinase PLK4 (refs. 2,3). When PLK4 is chemically inhibited, cell division proceeds without centrosome duplication, generating centrosome-less cells that exhibit delayed, acentrosomal spindle assembly4. Whether PLK4 inhibitors can be leveraged as a treatment for cancer is not yet clear. Here we show that acentrosomal spindle assembly following PLK4 inhibition depends on levels of the centrosomal ubiquitin ligase TRIM37. Low TRIM37 levels accelerate acentrosomal spindle assembly and improve proliferation following PLK4 inhibition, whereas high TRIM37 levels inhibit acentrosomal spindle assembly, leading to mitotic failure and cessation of proliferation. The Chr17q region containing the TRIM37 gene is frequently amplified in neuroblastoma and in breast cancer5–8, rendering these cancer types highly sensitive to PLK4 inhibition. We find that inactivating TRIM37 improves acentrosomal mitosis because TRIM37 prevents PLK4 from self-assembling into centrosome-independent condensates that serve as ectopic microtubule-organizing centres. By contrast, elevated TRIM37 expression inhibits acentrosomal spindle assembly through a distinct mechanism that involves degradation of the centrosomal component CEP192. Thus, TRIM37 is an essential determinant of mitotic vulnerability to PLK4 inhibition. Linkage of TRIM37 to prevalent cancer-associated genomic changes—including 17q gain in neuroblastoma and 17q23 amplification in breast cancer—may offer an opportunity to use PLK4 inhibition to trigger selective mitotic failure and provide new avenues to treatments for these cancers.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2710-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:585:y:2020:i:7825:d:10.1038_s41586-020-2710-1

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2710-1

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().